June 22, 2025 a 11:43 am
MRNA: Fundamental Ratio Analysis - Moderna, Inc.
Moderna, Inc., a leading biotechnology company, has been at the forefront in developing mRNA therapeutics and vaccines. The company's strategic alliances with major pharmaceutical firms and groundbreaking technologies position it uniquely within the healthcare sector. Investors should consider both the innovative edge and current market challenges.
Fundamental Rating
Moderna, Inc.'s current fundamental rating indicates areas of strength and others needing improvement. The balance between debt management and valuation remains key for investors.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 3 | |
| Return on Equity | 1 | |
| Return on Assets | 1 | |
| Debt to Equity | 3 | |
| Price to Earnings | 1 | |
| Price to Book | 4 |
Historical Rating
The historical performance provides insight into the development and shifts in Moderna's scores, which can guide future expectations.
| Date | Overall Score | DCF | ROE | ROA | Debt to Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-06-20 | 2 | 3 | 1 | 1 | 3 | 1 | 4 |
| Previous | 0 | 3 | 1 | 1 | 3 | 1 | 4 |
Analyst Price Targets
Analysts have a consensus hold rating on Moderna. Price targets suggest a stable outlook with some room for growth.
| High | Low | Median | Consensus |
|---|---|---|---|
| 50 | 45 | 47.5 | 47.5 |
Analyst Sentiment
The analyst sentiment indicates a mostly neutral stance with a significant number of 'buy' and 'hold' recommendations.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 9 | |
| Hold | 13 | |
| Sell | 3 | |
| Strong Sell | 0 |
Conclusion
Moderna, Inc. is a notable player in the biotechnology sector with robust partnerships and a promising product lineup. While fundamental scores suggest challenges, especially in profitability ratios like ROE and ROA, its competitive position and strategic alliances show potential. The market sentiment reflects cautious optimism, with most analysts recommending 'hold'. Investors should weigh innovation prospects against financial metrics before making decisions.